GlassScriptPhysician profile
M Yaser Mounla
NPI 1154399921
$8,678.46
in general payments reported to CMS, 2019-2025
62 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $429 · 2021: $1,379 · 2022: $2,124 · 2023: $1,314 · 2024: $1,549 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,552 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,551.69 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $982.53 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $873.36 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $509.72 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $487.52 | 2021-2025 | |
| Abbott Laboratories | $485.57 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Corcept Therapeutics | $401.39 | 2022-2025 | Korlym |
| Pfizer INC. | $336.15 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $285.70 | 2021-2024 | |
| Amgen INC. | $282.71 | 2021-2025 | Tavneos, Tepezza, Evenity |
| Astrazeneca Pharmaceuticals LP | $276.23 | 2020-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $265.89 | 2020-2023 | Steglatro, Belsomra, Steglujan |
| Mannkind Corporation | $241.98 | 2020-2025 | Afrezza |
| Travere Therapeutics, INC. | $170.51 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $164.93 | 2025 | Tarpeyo |
| Dexcom, INC. | $162.48 | 2019-2025 | Dexcom G6 Transmitter |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $154.78 | 2022-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Ani Pharmaceuticals, INC. | $152.96 | 2023-2024 | Purified Cortrophin Gel |
| Abbvie INC. | $148.95 | 2021-2024 | |
| Shield Therapeutics INC | $136.97 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $135.41 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $133.02 | 2020-2023 | Xarelto |
| Insulet Corporation | $118.30 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $116.29 | 2025 | Yorvipath |
| Mallinckrodt Hospital Products INC. | $115.07 | 2021-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $85.67 | 2022 | |
| Vifor Pharma, INC. | $84.58 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $82.65 | 2020-2025 | Unithroid |
| Medtronic, INC. | $81.43 | 2021-2025 | Minimed 780g |
| Biogen, INC. | $81.27 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $69.87 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $61.36 | 2024-2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $61.26 | 2021-2023 | |
| Tandem Diabetes Care, INC. | $60.80 | 2021-2022 | |
| Cequr Corporation | $60.09 | 2023-2024 | Cequr Simplicity |
| Ibsa Pharma INC. | $59.01 | 2020-2024 | Tirosint, Licart, Tirosint |
| Genzyme Corporation | $51.92 | 2021-2024 | |
| Amarin Pharma, INC. | $51.19 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $50.55 | 2025 | Isturisa |
| Fresenius USA Marketing, INC. | $47.59 | 2024-2025 | Velphoro, Nxstage System One |
| Glaxosmithkline, LLC. | $44.01 | 2021-2025 | Shingrix |
| Eisai INC. | $40.80 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $35.19 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $33.47 | 2023-2025 | Ingrezza |
| Globus Medical, INC. | $32.81 | 2025 | Senza |
| Lundbeck LLC | $26.68 | 2024 | Rexulti |
| Medtronic Minimed, INC. | $25.18 | 2020 | |
| Halozyme INC | $25.17 | 2023 | |
| Aimmune Therapeutics, INC. | $24.69 | 2024 | |
| Nevro Corp. | $24.56 | 2024 | Senza |
| Boston Scientific Corporation | $23.08 | 2024 | Watchman Flx |
| Vantive US Healthcare LLC | $21.94 | 2025 | Renal - Pd |
| Radius Health, INC. | $21.77 | 2020 | |
| Kyowa Kirin, INC. | $20.74 | 2021 | |
| Nxstage Medical, INC. | $19.99 | 2025 | Nxstage System One |
| Ardelyx, INC. | $19.68 | 2024 | Ibsrela |
| Scpharmaceuticals INC. | $19.50 | 2025 | |
| Lifescan, INC. | $17.30 | 2020 | |
| Melinta Therapeutics, LLC | $15.61 | 2024 | Orbactiv, Kimyrsa |
| Idorsia Pharmaceuticals US INC | $15.61 | 2024 | Quviviq |
| Sun Pharmaceutical Industries INC. | $14.64 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.22 | 2022 | |
| Madrigal Pharmaceuticals | $14.16 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Yaser Mounla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.